Recent Updates
Recently added Catalysts

Sanfilippo Syndrome (MPS IIIB): two biotech companies racing to a treatment

MPS IIIB (Sanfilippo Syndrome).Rare Genetic & MetabolicOrphan cornerData as of 2026-09-04

Competitors2in the clinic
Median market cap$815Muniverse median $1.20B
Allocated capital$654M$1.6B competing
Phase 3 or filed11 mid, 0 early
Pure plays1this indication only
Capital rank185/299crowding rank 94

Sanfilippo Syndrome (MPS IIIB) is a two-horse race: Spruce Biosciences (SPRB, $166M) against Ultragenyx Pharmaceutical (RARE, $1.5B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $654M of allocated capital sits on the pair.

RARE alone accounts for 90% of the $1.6B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$654M of allocated capital sits in Sanfilippo Syndrome (MPS IIIB), 185th of 299 indications, and 1 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Sanfilippo Syndrome (MPS IIIB) 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
SPRBSpruce BiosciencesTralesinidase alfaPhase 31$166MYes1 31 Dec 2026
RAREUltragenyx PharmaceuticalUX111Phase 24$1.5BNo3 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. RARE holds 90% of the $1.6B competing in this indication.

Why Sanfilippo Syndrome (MPS IIIB) is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Sanfilippo Syndrome (MPS IIIB) has 2 competitors and a median of $815M.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Erythropoietic Protoporphyria1 company · $609M · median $3.0BUncontestedMucopolysaccharidosis Type IIIA1 company · $729M · median $3.6BUncontestedLate-onset Pompe Disease1 company · $729M · median $3.6BUncontestedLimb-Girdle Muscular Dystrophy1 company · $809M · median $2.4BUncontestedOsteogenesis Imperfecta Type IV1 company · $488M · median $1.5BUncontestedConstipation Predominant Irritable Bowel Syndrome1 company · $462M · median $924MUncontestedParoxysmal Nocturnal Hemoglobinuria1 company · $461M · median $1.4BUncontestedGuillain-Barré Syndrome1 company · $459M · median $918MUncontested

Sanfilippo Syndrome (MPS IIIB) pipeline questions

Which biotech companies are developing drugs for Sanfilippo Syndrome (MPS IIIB)?

Spruce Biosciences (SPRB, Tralesinidase alfa, Phase 3); Ultragenyx Pharmaceutical (RARE, UX111, Phase 2). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Sanfilippo Syndrome (MPS IIIB).

How advanced is the Sanfilippo Syndrome (MPS IIIB) pipeline?

Of the 2 clinical-stage programmes in Sanfilippo Syndrome (MPS IIIB), 1 is in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Which company leads the Sanfilippo Syndrome (MPS IIIB) field?

RARE is the largest developer in Sanfilippo Syndrome (MPS IIIB), holding 90% of the $1.6B of market capitalisation competing in the indication. The median competitor is worth $815M.

When is the next Sanfilippo Syndrome (MPS IIIB) catalyst?

The next dated catalyst in Sanfilippo Syndrome (MPS IIIB) is RARE on 30 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map